الفهرس 
MicroRNAs as candidate biomarkers in systemic lupus erythematosus patients
AbstractOnly 14 pages are availabe for public view
 |  | from | 219 |  |  |
| | | from | 219 | | |
Abstract
Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease that can affect the major»ity of organs and tissues.The clinical presentations of SLE can range from mild to severe and the course is unpredictable, with periods of remission and flares. Lupus nephritis is a severe consequence of SLE and an important driver of morbidity and mortality in SLEMicroRNAs (miRNAs) are a class of small (” " ~ " ”22nucleotides) noncoding RNAs that modulate gene expression and regulate various cellular processes and are critically involved in many physiologic and pathologic processes in health and disease including immune system disease. Aim of work The aim of the study is to identify the use of microRNA-126 and microRNA-146a as candidate diagnostic and prognostic biomarkers and their correlation with disease activity in SLE patients Subjects and methods Our study included 74 SLE patients (66 females and 8 males) with ages ranging from 13 years to 57 years. Patients with SLE fulfilled the American College of Rheumatology classification criteria for SLE. Besides, our study included 40 age and sex matched healthy controls, for comparison. Determination of plasma levels of miR-146a and miR-126 were done using taqman quantitative Real time-PCR using RNU6B as internal controls.Measurement of serum interferon alpha (IFN-Ü) by ELISA technique was performed from SLE patients and healthy controls.Data was correlated with disease activity and hence evaluation of their prognosis. Results: The median value of fold change of plasma miR-146a levels showed a significant statistical decrease in SLE and lupus nephritis patients compared to the healthy control group and there was also a decrease in plasma levels of miR-146a in active SLE patients versus the inactive group and healthy control group. However, there was no statistical significant difference in plasma miR-126 levels and serum IFN-Ü in SLE and lupus nephritis patients compared to the healthy control group